1	Potent	potent	_	_	_	_	_	_	_
2	inhibition	inhibition	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	HIV	HIV	_	_	_	_	_	_	_
5	type	type	_	_	_	_	_	_	_
6	1	1	_	_	_	_	_	_	_
7	replication	replication	_	_	_	_	_	_	_
8	by	by	_	_	_	_	_	_	_
9	an	an	_	_	_	_	_	_	_
10	antiinflammatory	antiinflammatory	_	_	_	_	_	_	_
11	alkaloid	alkaloid	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	cepharanthine	cepharanthine	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	chronically	chronically	_	_	_	_	_	_	_
17	infected	infected	_	_	_	_	_	_	_
18	monocytic	monocytic	_	_	_	_	_	_	_
19	cells	cell	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	Cepharanthine	Cepharanthine	_	_	_	_	_	_	_
2	is	be	_	_	_	_	_	_	_
3	a	a	_	_	_	_	_	_	_
4	biscoclaurine	biscoclaurine	_	_	_	_	_	_	_
5	alkaloid	alkaloid	_	_	_	_	_	_	_
6	isolated	isolate	_	_	_	_	_	_	_
7	from	from	_	_	_	_	_	_	_
8	Stephania	Stephania	_	_	_	_	_	_	_
9	cepharantha	cepharantha	_	_	_	_	_	_	_
10	Hayata	Hayata	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	has	have	_	_	_	_	_	_	_
13	been	be	_	_	_	_	_	_	_
14	shown	show	_	_	_	_	_	_	_
15	to	to	_	_	_	_	_	_	_
16	have	have	_	_	_	_	_	_	_
17	antiinflammatory	antiinflammatory	_	_	_	_	_	_	_
18	,	,	_	_	_	_	_	_	_
19	antiallergic	antiallergic	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	and	and	_	_	_	_	_	_	_
22	immunomodulatory	immunomodulatory	_	_	_	_	_	_	_
23	activities	activity	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	vivo	vivo	_	_	_	_	_	_	_
26	.	.	_	_	_	_	_	_	_

1	As	as	_	_	_	_	_	_	_
2	several	several	_	_	_	_	_	_	_
3	inflammatory	inflammatory	_	_	_	_	_	_	_
4	cytokines	cytokine	_	_	_	_	_	_	_
5	and	and	_	_	_	_	_	_	_
6	oxidative	oxidative	_	_	_	_	_	_	_
7	stresses	stress	_	_	_	_	_	_	_
8	are	be	_	_	_	_	_	_	_
9	involved	involve	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	pathogenesis	pathogenesis	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	HIV-1	HIV-1	_	_	_	_	_	_	_
15	infection	infection	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	we	we	_	_	_	_	_	_	_
18	investigated	investigate	_	_	_	_	_	_	_
19	the	the	_	_	_	_	_	_	_
20	inhibitory	inhibitory	_	_	_	_	_	_	_
21	effects	effect	_	_	_	_	_	_	_
22	of	of	_	_	_	_	_	_	_
23	cepharanthine	cepharanthine	_	_	_	_	_	_	_
24	on	on	_	_	_	_	_	_	_
25	tumor	tumor	_	_	_	_	_	_	_
26	necrosis	necrosis	_	_	_	_	_	_	_
27	factor	factor	_	_	_	_	_	_	_
28	alpha	alpha	_	_	_	_	_	_	_
29	(	(	_	_	_	_	_	_	_
30	TNF-alpha)-	tnf-alpha)-	_	_	_	_	_	_	_
31	and	and	_	_	_	_	_	_	_
32	phorbol	phorbol	_	_	_	_	_	_	_
33	12-myristate	12-myristate	_	_	_	_	_	_	_
34	13-acetate	13-acetate	_	_	_	_	_	_	_
35	(	(	_	_	_	_	_	_	_
36	PMA)-induced	pma)-induced	_	_	_	_	_	_	_
37	HIV-1	HIV-1	_	_	_	_	_	_	_
38	replication	replication	_	_	_	_	_	_	_
39	in	in	_	_	_	_	_	_	_
40	chronically	chronically	_	_	_	_	_	_	_
41	infected	infected	_	_	_	_	_	_	_
42	cell	cell	_	_	_	_	_	_	_
43	lines	line	_	_	_	_	_	_	_
44	.	.	_	_	_	_	_	_	_

1	Two	two	_	_	_	_	_	_	_
2	chronically	chronically	_	_	_	_	_	_	_
3	HIV-1-infected	hiv-1-infected	_	_	_	_	_	_	_
4	cell	cell	_	_	_	_	_	_	_
5	lines	line	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	U1	u1	_	_	_	_	_	_	_
8	(	(	_	_	_	_	_	_	_
9	monocytic	monocytic	_	_	_	_	_	_	_
10	)	)	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	ACH-2	ach-2	_	_	_	_	_	_	_
13	(	(	_	_	_	_	_	_	_
14	T	t	_	_	_	_	_	_	_
15	lymphocytic	lymphocytic	_	_	_	_	_	_	_
16	)	)	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	were	be	_	_	_	_	_	_	_
19	stimulated	stimulate	_	_	_	_	_	_	_
20	with	with	_	_	_	_	_	_	_
21	TNF-alpha	TNF-alpha	_	_	_	_	_	_	_
22	or	or	_	_	_	_	_	_	_
23	PMA	PMA	_	_	_	_	_	_	_
24	and	and	_	_	_	_	_	_	_
25	cultured	culture	_	_	_	_	_	_	_
26	in	in	_	_	_	_	_	_	_
27	the	the	_	_	_	_	_	_	_
28	presence	presence	_	_	_	_	_	_	_
29	of	of	_	_	_	_	_	_	_
30	various	various	_	_	_	_	_	_	_
31	concentrations	concentration	_	_	_	_	_	_	_
32	of	of	_	_	_	_	_	_	_
33	the	the	_	_	_	_	_	_	_
34	compound	compound	_	_	_	_	_	_	_
35	.	.	_	_	_	_	_	_	_

1	HIV-1	HIV-1	_	_	_	_	_	_	_
2	replication	replication	_	_	_	_	_	_	_
3	was	be	_	_	_	_	_	_	_
4	determined	determine	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	p24	p24	_	_	_	_	_	_	_
7	antigen	antigen	_	_	_	_	_	_	_
8	level	level	_	_	_	_	_	_	_
9	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	inhibitory	inhibitory	_	_	_	_	_	_	_
3	effects	effect	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	cepharanthine	cepharanthine	_	_	_	_	_	_	_
6	on	on	_	_	_	_	_	_	_
7	HIV-1	HIV-1	_	_	_	_	_	_	_
8	long	long	_	_	_	_	_	_	_
9	terminal	terminal	_	_	_	_	_	_	_
10	repeat	repeat	_	_	_	_	_	_	_
11	(	(	_	_	_	_	_	_	_
12	LTR)-driven	ltr)-driven	_	_	_	_	_	_	_
13	gene	gene	_	_	_	_	_	_	_
14	expression	expression	_	_	_	_	_	_	_
15	and	and	_	_	_	_	_	_	_
16	nuclear	nuclear	_	_	_	_	_	_	_
17	factor	factor	_	_	_	_	_	_	_
18	kappaB	kappaB	_	_	_	_	_	_	_
19	(	(	_	_	_	_	_	_	_
20	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
21	)	)	_	_	_	_	_	_	_
22	activation	activation	_	_	_	_	_	_	_
23	were	be	_	_	_	_	_	_	_
24	also	also	_	_	_	_	_	_	_
25	examined	examine	_	_	_	_	_	_	_
26	.	.	_	_	_	_	_	_	_

1	Cepharanthine	Cepharanthine	_	_	_	_	_	_	_
2	dose	dose	_	_	_	_	_	_	_
3	dependently	dependently	_	_	_	_	_	_	_
4	inhibited	inhibit	_	_	_	_	_	_	_
5	HIV-1	HIV-1	_	_	_	_	_	_	_
6	replication	replication	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	TNF-alpha-	tnf-alpha-	_	_	_	_	_	_	_
9	and	and	_	_	_	_	_	_	_
10	PMA-stimulated	pma-stimulated	_	_	_	_	_	_	_
11	U1	u1	_	_	_	_	_	_	_
12	cells	cell	_	_	_	_	_	_	_
13	but	but	_	_	_	_	_	_	_
14	not	not	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	ACH-2	ach-2	_	_	_	_	_	_	_
17	cells	cell	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	Its	its	_	_	_	_	_	_	_
2	50	50	_	_	_	_	_	_	_
3	%	%	_	_	_	_	_	_	_
4	effective	effective	_	_	_	_	_	_	_
5	and	and	_	_	_	_	_	_	_
6	cytotoxic	cytotoxic	_	_	_	_	_	_	_
7	concentrations	concentration	_	_	_	_	_	_	_
8	were	be	_	_	_	_	_	_	_
9	0.016	0.016	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	2.2	2.2	_	_	_	_	_	_	_
12	microg/ml	microg/ml	_	_	_	_	_	_	_
13	in	in	_	_	_	_	_	_	_
14	PMA-stimulated	pma-stimulated	_	_	_	_	_	_	_
15	U1	u1	_	_	_	_	_	_	_
16	cells	cell	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	respectively	respectively	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	Cepharanthine	Cepharanthine	_	_	_	_	_	_	_
2	was	be	_	_	_	_	_	_	_
3	found	find	_	_	_	_	_	_	_
4	to	to	_	_	_	_	_	_	_
5	suppress	suppress	_	_	_	_	_	_	_
6	HIV-1	HIV-1	_	_	_	_	_	_	_
7	LTR-driven	ltr-driven	_	_	_	_	_	_	_
8	gene	gene	_	_	_	_	_	_	_
9	expression	expression	_	_	_	_	_	_	_
10	through	through	_	_	_	_	_	_	_
11	the	the	_	_	_	_	_	_	_
12	inhibition	inhibition	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
15	activation	activation	_	_	_	_	_	_	_
16	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	results	result	_	_	_	_	_	_	_
3	indicate	indicate	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	cepharanthine	cepharanthine	_	_	_	_	_	_	_
6	is	be	_	_	_	_	_	_	_
7	a	a	_	_	_	_	_	_	_
8	highly	highly	_	_	_	_	_	_	_
9	potent	potent	_	_	_	_	_	_	_
10	inhibitor	inhibitor	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	HIV-1	HIV-1	_	_	_	_	_	_	_
13	replication	replication	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	a	a	_	_	_	_	_	_	_
16	chronically	chronically	_	_	_	_	_	_	_
17	infected	infected	_	_	_	_	_	_	_
18	monocytic	monocytic	_	_	_	_	_	_	_
19	cell	cell	_	_	_	_	_	_	_
20	line	line	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

1	Since	since	_	_	_	_	_	_	_
2	biscoclaurine	biscoclaurine	_	_	_	_	_	_	_
3	alkaloids	alkaloid	_	_	_	_	_	_	_
4	,	,	_	_	_	_	_	_	_
5	containing	contain	_	_	_	_	_	_	_
6	cepharanthine	cepharanthine	_	_	_	_	_	_	_
7	as	as	_	_	_	_	_	_	_
8	a	a	_	_	_	_	_	_	_
9	major	major	_	_	_	_	_	_	_
10	component	component	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	are	be	_	_	_	_	_	_	_
13	widely	widely	_	_	_	_	_	_	_
14	used	use	_	_	_	_	_	_	_
15	for	for	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	treatment	treatment	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	patients	patient	_	_	_	_	_	_	_
20	with	with	_	_	_	_	_	_	_
21	various	various	_	_	_	_	_	_	_
22	inflammatory	inflammatory	_	_	_	_	_	_	_
23	diseases	disease	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	Japan	Japan	_	_	_	_	_	_	_
26	,	,	_	_	_	_	_	_	_
27	cepharanthine	cepharanthine	_	_	_	_	_	_	_
28	should	should	_	_	_	_	_	_	_
29	be	be	_	_	_	_	_	_	_
30	further	further	_	_	_	_	_	_	_
31	pursued	pursue	_	_	_	_	_	_	_
32	for	for	_	_	_	_	_	_	_
33	its	its	_	_	_	_	_	_	_
34	chemotherapeutic	chemotherapeutic	_	_	_	_	_	_	_
35	potential	potential	_	_	_	_	_	_	_
36	in	in	_	_	_	_	_	_	_
37	HIV-1-infected	hiv-1-infected	_	_	_	_	_	_	_
38	patients	patient	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

